JP2010516708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516708A5 JP2010516708A5 JP2009546582A JP2009546582A JP2010516708A5 JP 2010516708 A5 JP2010516708 A5 JP 2010516708A5 JP 2009546582 A JP2009546582 A JP 2009546582A JP 2009546582 A JP2009546582 A JP 2009546582A JP 2010516708 A5 JP2010516708 A5 JP 2010516708A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims description 57
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 201000011510 cancer Diseases 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 31
- 230000000975 bioactive effect Effects 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 230000002950 deficient Effects 0.000 claims description 20
- 210000004408 hybridoma Anatomy 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 12
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 12
- 201000010881 cervical cancer Diseases 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 206010027476 Metastases Diseases 0.000 claims description 9
- 230000009401 metastasis Effects 0.000 claims description 9
- 229940127121 immunoconjugate Drugs 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010005949 Bone cancer Diseases 0.000 claims description 6
- 208000018084 Bone neoplasm Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 6
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 201000003163 breast adenoma Diseases 0.000 claims description 6
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 6
- 239000002532 enzyme inhibitor Substances 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 238000007911 parenteral administration Methods 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 206010046766 uterine cancer Diseases 0.000 claims description 6
- 230000025084 cell cycle arrest Effects 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 230000006882 induction of apoptosis Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 230000007718 nuclear exclusion Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 56
- 210000003462 vein Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 description 58
- 238000001990 intravenous administration Methods 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89701207P | 2007-01-22 | 2007-01-22 | |
| PCT/US2008/051734 WO2008091911A2 (en) | 2007-01-22 | 2008-01-22 | Use of antibody conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010516708A JP2010516708A (ja) | 2010-05-20 |
| JP2010516708A5 true JP2010516708A5 (enExample) | 2012-03-01 |
Family
ID=39645132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009546582A Pending JP2010516708A (ja) | 2007-01-22 | 2008-01-22 | 抗体結合体の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100143358A1 (enExample) |
| EP (1) | EP2109625A4 (enExample) |
| JP (1) | JP2010516708A (enExample) |
| AU (1) | AU2008207948A1 (enExample) |
| CA (1) | CA2676234A1 (enExample) |
| WO (1) | WO2008091911A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009070650A1 (en) * | 2007-11-26 | 2009-06-04 | The Research Foundation Of State University Of New York | Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells |
| WO2010044894A1 (en) | 2008-10-15 | 2010-04-22 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotonic dystrophy |
| EP2438090B1 (en) * | 2009-05-28 | 2016-07-06 | The United States Government as Represented by the Department of Veterans Affairs | Amino acid sequences which enhance peptide conjugate solubility |
| BRPI1011236A2 (pt) | 2009-06-15 | 2019-07-09 | 4S3 Bioscience Inc | métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1) |
| EP3597665A1 (en) * | 2011-04-01 | 2020-01-22 | Yale University, Inc. | Cell-penetrating anti-dna antibodies and uses thereof to inhibit dna repair |
| CA2832184A1 (en) * | 2011-04-07 | 2012-10-11 | Memorial Sloan Kettering Cancer Center | Anti-tumor antibody-tumor suppressor fusion protein compositions and methods of use for the treatment of cancer |
| WO2013138662A1 (en) | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
| US9283272B2 (en) * | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| US12195550B2 (en) | 2012-03-30 | 2025-01-14 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| US20150152170A1 (en) * | 2012-05-23 | 2015-06-04 | Valerion Therapeutics, Llc | Methods for increasing muscle contractility |
| AU2014218854B2 (en) | 2013-02-20 | 2019-01-24 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
| JP6709733B2 (ja) * | 2014-01-13 | 2020-06-17 | バレリオン セラピューティクス， エルエルシー | 内在化部分 |
| WO2015134607A1 (en) | 2014-03-04 | 2015-09-11 | Yale University | Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations |
| US10238742B2 (en) | 2014-06-25 | 2019-03-26 | Yale University | Cell penetrating nucleolytic antibody based cancer therapy |
| EP3186278A4 (en) | 2014-08-27 | 2018-04-04 | Valerion Therapeutics, LLC | Internalizing moieties for treatment of cancer |
| CN109069644B (zh) | 2015-10-08 | 2022-10-28 | 犹他大学研究基金会 | 用于预防或治疗癌症的方法和组合物 |
| US11016085B2 (en) | 2016-04-25 | 2021-05-25 | The Johns Hopkins University | ZNT8 assays for drug development and pharmaceutical compositions |
| WO2017218824A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| EP3471777A1 (en) | 2016-06-15 | 2019-04-24 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
| CN111316099A (zh) | 2017-07-12 | 2020-06-19 | 约翰霍普金斯大学 | 用于1型糖尿病诊断的基于脂蛋白体的znt8自身抗原 |
| WO2019152806A1 (en) * | 2018-02-01 | 2019-08-08 | Yale University | Compositions and methods for enhancing nuclear translocation |
| CA3096978A1 (en) | 2018-04-06 | 2019-10-10 | Oncolyze, Inc. | Compositions for use in lysis of selective cancer cells |
| CN113166241B (zh) | 2018-08-16 | 2025-02-25 | 约翰霍普金斯大学 | 人类znt8抗体 |
| MX2021002265A (es) | 2018-08-31 | 2021-05-27 | Univ Yale | Composiciones y métodos para aumentar la edición genética basada en oligonucleótidos de donador. |
| CN115151275A (zh) | 2019-08-30 | 2022-10-04 | 耶鲁大学 | 用于向细胞递送核酸的组合物和方法 |
| US12366570B2 (en) | 2019-10-01 | 2025-07-22 | The Johns Hopkins University | Cell-based ZNT8 assay |
| EP4387666A4 (en) * | 2021-08-20 | 2025-07-16 | Univ Johns Hopkins | CELL SURFACE ANTIBODY FOR A PANCREATIC BETA CELL SPECIFIC BIOMARKER |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4812397A (en) * | 1987-02-10 | 1989-03-14 | The Regents Of The University Of California | MAB-anti-DNA related to nephritis |
| CA2248233A1 (en) * | 1996-03-08 | 1997-09-12 | The Regents Of The University Of California | Delivery system using mab 3e10 and mutants and/or functional fragments thereof |
| WO2001019393A1 (en) * | 1999-09-13 | 2001-03-22 | Cornell Research Foundation, Inc. | Delivering to eucaryotic cells bacterial proteins that are secreted via type iii secretion systems |
-
2008
- 2008-01-22 JP JP2009546582A patent/JP2010516708A/ja active Pending
- 2008-01-22 EP EP08713907A patent/EP2109625A4/en not_active Withdrawn
- 2008-01-22 AU AU2008207948A patent/AU2008207948A1/en not_active Abandoned
- 2008-01-22 WO PCT/US2008/051734 patent/WO2008091911A2/en not_active Ceased
- 2008-01-22 CA CA002676234A patent/CA2676234A1/en not_active Abandoned
- 2008-01-22 US US12/523,438 patent/US20100143358A1/en not_active Abandoned
-
2016
- 2016-09-15 US US15/266,919 patent/US20170096497A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516708A5 (enExample) | ||
| JP2021106617A5 (enExample) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| CA2747064C (en) | Monoclonal antibodies directed against lg4/5 domain of alpha3 chain of human laminin-5 | |
| JP2016533721A5 (enExample) | ||
| RU2018114904A (ru) | Антитело против garp | |
| JP2012502938A5 (enExample) | ||
| JP2014158469A5 (enExample) | ||
| RU2009149205A (ru) | Моноклональные антитела против клаудина-18 для лечения рака | |
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| RU2013152164A (ru) | Анти-в7-н3-антитело | |
| SI2342234T1 (en) | MONOCOLIC ANTI-GT468 CANCER CANCER PROTITEL | |
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| WO2012113266A1 (zh) | 识别肿瘤起始细胞的抗体和抗原及其应用 | |
| JP2019205480A5 (enExample) | ||
| JP2010509931A5 (enExample) | ||
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| JP2019513410A5 (enExample) | ||
| TW201713700A (zh) | 抗ｇｌｙｐｉｃａｎ-３抗體及其用於診斷及治療癌症之用途 | |
| JP2018529661A5 (enExample) | ||
| CN115605513A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
| JP2007526891A5 (enExample) | ||
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 |